Trial Profile
Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms MPACT
- 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2011 Planned end date changed from 1 Jan 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 28 Sep 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01442974)